news

New J&J data signals progress in ulcerative colitis treatment landscape

5
SHARES

The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.

Tremfya ulcerative colitis Johnson & Johnson

New clinical findings show that Johnson & Johnson’s monoclonal antibody Tremfya ® (guselkumab) enabled sustained clinical and endoscopic efficacy for ulcerative colitis patients at two years.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

This is based on the long-term extension study of the Phase III QUASAR trial, which evaluated adults with moderately-to-severely active forms of the disease.

At Week 92, Tremfya enabled:

• Clinical remission in 72 percent of patients
• Of these patients, 99 percent were not taking corticosteroid treatment for eight weeks or longer
• Endoscopic remission in 43 percent of patients in the long-term extension study
• Of patients who attained an improved endoscopic result at Week 44, 84 percent were able to maintain this through Week 92.

Tremfya is the first approved dual-acting monoclonal antibody that blocks the cytokine IL-23 while simultaneously binding to CD64, a receptor that produces IL-23, Johnson & Johnson shared.

“With these findings, Tremfya shows the powerful impact it can have in achieving longer term remission in [ulcerative colitis] patients”

“With these findings, Tremfya shows the powerful impact it can have in achieving longer term remission in [ulcerative colitis] patients,” commented Dr Esi Lamousé-Smith, PhD, Vice President, Gastroenterology Disease Area Lead, Immunology, Johnson & Johnson Innovative Medicine.

Safety data were consistent with the previous reported safety profile for Tremfya in inflammatory bowel disease (IBD).

The new findings are being shown at Digestive Disease Week (DDW) 2025 (presentation #4241842).

Building on clinical evidence for Tremfya in ulcerative colitis and Crohn’s disease

This new data adds to earlier clinical results released in May 2024 from a maintenance study of Tremfya in ulcerative colitis.

The US Food and Drug Administration (FDA) most recently approved Tremfya in March 2025 for adult patients with Crohn’s disease, for subcutaneous and intravenous induction administration options.

In October last year, Johnson & Johnson presented promising Phase III data for the monoclonal antibody in Crohn’s disease at the American College of Gastroenterology (ACG) 2024 conference.

In September 2024, the US FDA granted approval for intravenous administration of the drug in adults with ulcerative colitis. This indication consists of follow up subcutaneous maintenance treatment.

Share via
Share via